Loading the section…

STOK: financial statements from SEC — TradeAlmanac

STOK

Stoke Therapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	6M	11M	14M	159M	5M	5M
Research and development	40M	38M	26M	33M	22M	21M
Selling, general and administrative	20M	16M	15M	15M	13M	13M
Operating expenses	60M	54M	41M	47M	35M	34M
Operating income	−53M	−43M	−27M	111M	−30M	−29M
Pre-tax income	−50M	−40M	−23M	114M	−26M	−26M
Income tax	0	−1M	0	1M	0	0
Net income	−50M	−38M	−23M	113M	−26M	−26M
Earnings per share	−0.79	−0.65	−0.40	1.95	−0.47	−0.46
Earnings per share, diluted	−0.79	−0.65	−0.40	1.90	−0.47	−0.46
Weighted average shares	63M	59M	58M	58M	56M	56M
Weighted average shares, diluted	63M	59M	58M	59M	56M	56M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	156M	84M	83M	101M	275M	128M	150M	193M
Receivables	4M	6M	9M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−61M	132M
Depreciation and amortisation	439,000	477,000
Share-based compensation	9M	7M
Capital expenditure	353,000	152,000
Investing cash flow	51M	14M
Financing cash flow	84M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator